ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders
Authors:
- Stefania DemuroSDStefania Demuro
- Conall SauveyCSConall Sauvey
- Shailesh K. TripathiSTShailesh K. Tripathi
- Rita M.C. Di MartinoRMRita M.C. Di Martino
- Da ShiDSDa Shi
- Jose A. OrtegaJOJose A. Ortega
- Debora RussoDRDebora Russo
- Beatrice BalboniBBBeatrice Balboni
- Barbara GiabbaiBGBarbara Giabbai
- Paola StoriciPaola Storici
- Stefania GirottoSGStefania Girotto
- Ruben AbagyanRARuben Abagyan
- 16 December 2021
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 229, 114054
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- How good are my data and what is the resolution?Acta Crystallographica Section D Structural Biology, 2013
- Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate RecognitionStructure, 2013
- Docking and scoring with ICM: the benchmarking results and strategies for improvementJournal of Computer-Aided Molecular Design, 2012
- iMOSFLM: a new graphical interface for diffraction-image processing withMOSFLMActa Crystallographica Section D Structural Biology, 2011
- GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSFrontiers in Molecular Neuroscience, 2011
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down SyndromeJournal of Biological Chemistry, 2008
- Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndromeThe FASEB Journal, 2008
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Refinement of Macromolecular Structures by the Maximum-Likelihood MethodActa Crystallographica Section D Structural Biology, 1997